EIF4A3‐Mediated Biogenesis of CircFADS1 Promotes the Progression of Hepatocellular Carcinoma via Wnt/β‐Catenin Pathway
Source abstract
Abstract
Abstract Mounting research indicates that circRNAs are pivotal elements in tumorigenesis and progression. Understanding the mechanisms by which circRNAs function in tumors is crucial for identifying undiscovered diagnostic and treatment targets. This research centers on unraveling the mechanisms by which the novel circRNA, circFADS1, influences hepatocellular carcinoma (HCC) progression. CircFADS1 shows elevated expression in HCC and is linked to unfavorable prognosis. Functionally, circFADS1 overexpression accelerates HCC progression through inducing HCC proliferation and inhibited apoptosis. Mechanistically, RNA‐seq analysis demonstrates its connection to the Wnt/β‐catenin pathway. Moreover, circFADS1 interacts with GSK3β and promotes its ubiquitination and degradation by recruiting the ubiquitin ligase RNF114 while EIF4A3 facilitates the biogenesis of circFADS1. Additionally, circFADS1 is closely linked to lenvatinib resistance. Overall, this study reveals that circFADS1 regulates GSK3β function, influencing the progression of hepatocellular carcinoma. The EIF4A3/circFADS1/GSK3β/β‐catenin axis is discovered to hold promise as a novel therapeutic target for hepatocellular carcinoma, while circFADS1 is also a significant factor in lenvatinib resistance.
Source: crossref · Quality: baseline
Research context
OpenAlex topics: Circular RNAs in diseases · MicroRNA in disease regulation · RNA modifications and cancer
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Hepatobiliary Center The First Affiliated Hospital of Nanjing Medical University Key Laboratory of Liver Transplantation Chinese Academy of Medical Sciences NHC Key Laboratory of Living Donor Liver Transplantation (Nanjing Medical University) No. 300 Guangzhou Road Nanjing Jiangsu 210029 China
Medical College Yangzhou University Yangzhou Jiangsu 225009 China
Funding
National Natural Science Foundation of China
References (43)
Show source-provided references
1. 10.3322/caac.2183410.3322/caac.21834 ↗
2. 10.1111/liv.1281810.1111/liv.12818 ↗
3. 10.1016/j.ijsu.2020.04.04310.1016/j.ijsu.2020.04.043 ↗
4. 10.1038/s41392-020-00264-x10.1038/s41392-020-00264-x ↗
5. 10.1038/s41571-018-0073-410.1038/s41571-018-0073-4 ↗
6. 10.1038/s41576-019-0158-710.1038/s41576-019-0158-7 ↗
7. 10.1038/d41586-023-03058-710.1038/d41586-023-03058-7 ↗
8. 10.1038/s41571-021-00585-y10.1038/s41571-021-00585-y ↗
9. 10.1186/s12943-017-0663-210.1186/s12943-017-0663-2 ↗
10. 10.1080/21655979.2022.203640610.1080/21655979.2022.2036406 ↗
11. 10.1186/s12943-021-01383-x10.1186/s12943-021-01383-x ↗
12. 10.1038/s41467-023-40212-110.1038/s41467-023-40212-1 ↗
13. 10.1186/s13046-022-02494-z10.1186/s13046-022-02494-z ↗
14. 10.3389/fonc.2022.87851310.3389/fonc.2022.878513 ↗
15. 10.1261/rna.043687.11310.1261/rna.043687.113 ↗
16. 10.1038/s41392-021-00701-510.1038/s41392-021-00701-5 ↗
17. 10.3389/fimmu.2019.0229310.3389/fimmu.2019.02293 ↗
18. 10.1021/acs.jmedchem.4c0058310.1021/acs.jmedchem.4c00583 ↗
19. 10.1038/s41580-020-0243-y10.1038/s41580-020-0243-y ↗
20. 10.1016/j.trecan.2020.01.01210.1016/j.trecan.2020.01.012 ↗
21. 10.1038/srep3498510.1038/srep34985 ↗
22. 10.1038/s41467-017-01216-w10.1038/s41467-017-01216-w ↗
23. 10.1038/s41392-020-0111-410.1038/s41392-020-0111-4 ↗
24. 10.1038/nsmb.278010.1038/nsmb.2780 ↗
25. 10.1186/s12943-022-01653-210.1186/s12943-022-01653-2 ↗
26. 10.1016/j.cell.2015.02.01410.1016/j.cell.2015.02.014 ↗
27. 10.1038/s41467-023-35998-z10.1038/s41467-023-35998-z ↗
28. 10.1080/15476286.2015.112806510.1080/15476286.2015.1128065 ↗
29. 10.1016/j.semcancer.2020.12.02610.1016/j.semcancer.2020.12.026 ↗
30. 10.1186/s13045-021-01145-810.1186/s13045-021-01145-8 ↗
31. 10.1038/onc.2016.30410.1038/onc.2016.304 ↗
32. 10.1172/JCI15451510.1172/JCI154515 ↗
33. 10.1038/s41417-022-00489-810.1038/s41417-022-00489-8 ↗
34. 10.1016/j.canlet.2008.05.04510.1016/j.canlet.2008.05.045 ↗
35. 10.7150/jca.6203310.7150/jca.62033 ↗
36. 10.1126/sciadv.adg775210.1126/sciadv.adg7752 ↗
37. 10.1007/s40265-019-01116-x10.1007/s40265-019-01116-x ↗
38. 10.2174/156800962266622042811132710.2174/1568009622666220428111327 ↗
39. 10.1158/0008-5472.CAN-21-414010.1158/0008-5472.CAN-21-4140 ↗
40. 10.1158/0008-5472.CAN-22-096310.1158/0008-5472.CAN-22-0963 ↗
41. 10.1080/15548627.2022.211789310.1080/15548627.2022.2117893 ↗
42. 10.1186/s12943-020-01281-810.1186/s12943-020-01281-8 ↗
43. 10.1111/j.1525-1594.2007.00524.x10.1111/j.1525-1594.2007.00524.x ↗